Clinical Trial Update: Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial assessing repeated-dose oral N-acetylcysteine for treating Parkinson's disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: University of Minnesota | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED | Results posted: 2019-05-16